FDA gives new Biogen Alzheimer's treatment priority status

An Alzheimer’s treatment developed by Biogen and a partner has been granted priority status by the FDA, giving it an accelerated approval process.
by marketwire, translated by catherine brett

The FDA has granted US-based Biogen and Japanese firm Eisai priority status for another Alzheimer’s treatment, lecanemab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading